Skip to main content

Highlights

  1. 1
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024
    PMID: 38750866DOISenior author43 citations
  2. 2
    Surgical endoscopy · 2024
    PMID: 38467859DOISenior author2 citations
  3. 3
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024
    PMID: 38777170DOISenior author9 citations

Publications

276 publications

Active

1 grant
  • Co-I
    PREcision MEDicine In Achalasia: The PREMEDIA trial
    National Institute of Diabetes and Digestive and Kidney Diseases · 2025–2030 · via Northwestern University
    U01DK142700-01
Completed grants (1)
  • MPI
    Support a clinical fellow to attend the 37th year of the course, "Medical and Surgical Aspects of Esophageal and Foregut
    Medtronic, Inc. · 2022–2022
    MDT220022112

Clinical research

4 studies

Active

1 study
  • PI
    A Phase 2, Randomized, Double-Blind, Multi-Center Study in Adult Subjects With Eosinophilic Esophagitis (EoE) to Evaluate the Safety and Efficacy of Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate the Safety and Efficacy of Vonoprazan 20 mg Up to 24 Weeks
    PHASE2 · Phathom Pharmaceuticals Inc. · OPEN TO ACCRUAL (as of 2026)
    Eosinophilic Esophagitis
    NCT06851559
Completed & closed trials (3)
  • PI
    Prospective Observational Trial on Efficacy of Different Treatment Modalities in Patients with Eosinophilic Esophagitis
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2022)
  • PI
    Risk Stratification of BE Patients for Risk of Progression to Esophageal Adenocarcinoma using Mutational Load (ML) (i.e. BarreGEN®)
    Interpace Diagnostics · IRB STUDY CLOSURE (as of 2022)
  • PI
    A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients With Gastroesophageal Reflux Disease While Receiving Proton Pump Inhibitors
    PHASE3 · Ironwood Pharmaceuticals, Inc. · IRB STUDY CLOSURE (as of 2020)
    Gastroesophageal Reflux Disease (GERD)
    NCT03561090
  • RF
    Rhea Fogla
    MD mentee · Class of 2022
  • DS
    Daniel Skaf
    MD mentee · Class of 2021

External relationships

Leadership Roles

The American Foregut Society

Other

Braintree Laboratories, INC · Carelon Research · Eli Lilly and Company · Medtronic, Inc. · Phathom Pharmaceuticals Inc.